# US 8,591,910 B2 · Chemically programmable immunity > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 8,591,910 B2 - Document ID: US8591910B2 - Status: Granted - Kind: B2 - Application number: 13/543,718 - Filed: 2012-07-06 - Published: 2012-11-01 - Granted: 2013-11-26 - Earliest claimed: 1999-12-22 - Assignees: Altermune Technologies, LLC - Applicants: Kary B. Mullis - Inventors: Kary B. Mullis - Web page: https://patentgrep.com/patent/US8591910B2 ## CPC - A61K 39/385: Haptens or antigens, bound to carriers - A61P 37/04: Immunostimulants - A61K 2039/6025: {Nucleotides} - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule. ## Claims ### Claim 1 An immune-diverting composition comprising an immunity linker molecule comprising a first binding site that when administered to an individual is capable of binding to an antibody produced from a pre-existing immunity within the individual specific for a first compound or molecule, and a second binding site comprising a nucleic acid aptamer or a modified nucleic acid aptamer that is capable of binding to a target, wherein the first compound or molecule and the target are not the same. ### Claim 2 (depends on 1) The immune-diverting composition of claim 1, wherein the composition comprises an amount of the immunity linker molecule effective to provide substantially immediate immunity to the target. ### Claim 3 (depends on 1) The immune-diverting composition of claim 1, wherein the pre-existing immunity is induced by an immunizing molecule and optionally an adjuvant or a booster. ### Claim 4 (depends on 1) The immune-diverting composition of claim 1, wherein the immunity linker molecule comprises more than one second binding site. ### Claim 5 (depends on 4) The immune-diverting composition of claim 4, wherein the binding sites differ in specificity for targets. ### Claim 6 (depends on 1) The immune-diverting composition of claim 1, wherein the aptamer comprises a modified nucleic acid aptamer, and wherein the modified nucleic acid comprises 2′-fluoro or 2′-amino-2′deoxypyrimidine. ### Claim 7 (depends on 1) The immune-diverting composition of claim 1 further comprising a linking portion linking the first and second binding sites. ### Claim 8 (depends on 7) The immune-diverting composition of claim 7, wherein the linking portion comprises a rigid or flexible spacer. ### Claim 9 (depends on 8) The immune-diverting composition of claim 8, wherein the spacer is double stranded nucleic acid. ### Claim 10 (depends on 1) The immune-diverting composition of claim 1, wherein the immunity linker further comprises a protein, a peptide, a nucleic acid, or a combination thereof. ### Claim 11 (depends on 1) The immune-diverting composition of claim 1, wherein the target comprises a microorganism, a pathogen, a toxic substance, or a drug. ### Claim 12 (depends on 11) The immune-diverting composition of claim 11, wherein the microorganism is a bacterium, a virus, or a fungus. ### Claim 13 (depends on 1) The immune-diverting composition of claim 1, wherein the target comprises anthrax or a dengue virus. ### Claim 14 (depends on 1) The immune-diverting composition of claim 1, wherein the individual is unable to mount an effective immune response to the target compound or molecule prior to administration of the composition. ### Claim 15 (depends on 1) The immune-diverting composition of claim 1, wherein the composition is in a form suitable for at least one administration mode selected from the group consisting of intravenous administration, intramuscular administration, subcutaneous administration, oral administration, and mucosal administration. ### Claim 16 (depends on 1) A method of establishing substantially immediate immunity to a target in an individual comprising, wherein the method comprises administering to the individual an effective amount of the immune-diverting composition of claim 1. ### Claim 17 (depends on 16) The method of claim 16, wherein the individual is unable to mount an effective immune response to the target prior to the administering step. ### Claim 18 (depends on 16) The method of claim 16, wherein the immunity to the target is a cellular or humoral immunity.